Vusolimogene oderparepvec (Tudriqev)
Oncolytic virus
Evidence outlook
Approved: Melanoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Non-Small Cell Lung Cancer · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
IGNYTE NCT03767348 · Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma Registry: NCT03767348 | 2 | Percentage of adverse events (AEs) (26 months); Percentage of serious adverse events (SAEs) (26 months); Percentage of dose limiting toxicities (DLTs) (26 months); Percentage of overall response rate (ORR) (26 months); Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1 (20 weeks) 2028-06 | In progress: results expected 1 Jun 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other No discrete molecular target drugs
Olvimulogene nanivacirepvec, LN-145, Adipose-derived MSC clusters (S.Biomedics), BGC101, SL-28 and 2 more. Compare all 8 No discrete molecular target drugs
7 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Melanoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vusolimogene Oderparepvec (Tudriqev): this drug | Approved | Oncolytic virus | No discrete molecular target | not yet graded | No reviewed efficacy summary in this indication | |
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Binimetinib | Approved | Small molecule | MEK1/2 | Partial signal | NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71) | |
| Cobimetinib | Approved | Small molecule | MEK1/2 | Reliable signal | No reviewed efficacy summary in this indication | |
| Dabrafenib | Approved | Small molecule | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF) | Reliable signal | NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7) NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3) | |
| Encorafenib | Approved | Small molecule | BRAF V600E | Partial signal | No reviewed efficacy summary in this indication | |
| Interferon Alfa-2b (Intron A) | Approved | Biologic (subtype unspecified) | Type I interferon receptor | Partial signal | NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | Partial signal | NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71) | |
| Lifileucel (Amtagvi) | Approved | Cell therapy | Tumor-infiltrating lymphocytes (polyclonal tumor antigens) | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09) NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Relatlimab | Approved | Monoclonal antibody | LAG-3 | Reliable signal | NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62) | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Trametinib | Approved | Small molecule | MEK1/2 | Weak signal | No reviewed efficacy summary in this indication | |
| Vemurafenib | Approved | Small molecule | BRAF (V600 mutant) | Partial signal | No reviewed efficacy summary in this indication | |
| Cemiplimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Fianlimab | Phase 3 | Monoclonal antibody | LAG-3 | not yet graded | No reviewed efficacy summary in this indication | |
| Intismeran Autogene | Phase 3 | Vaccine | Patient-specific tumor neoantigens (personalized, up to 34 per patient) | not yet graded | No reviewed efficacy summary in this indication | |
| Tebentafusp-Tebn (KIMMTRAK) | Phase 3 | Protein / enzyme therapeutic | gp100-HLA-A*02:01 x CD3 | Partial signal | No reviewed efficacy summary in this indication | |
| LNS8801 | Phase 2/3 | Small molecule | GPER (G protein-coupled estrogen receptor) | not yet graded | No reviewed efficacy summary in this indication | |
| Resiquimod | Phase 2/3 | Small molecule | Toll-like receptor 7 and 8 (TLR7/8) | not yet graded | No reviewed efficacy summary in this indication | |
| HS-IT101 | Phase 2 | Cell therapy | Autologous tumor neoantigens (polyclonal, patient-specific) | not yet graded | No reviewed efficacy summary in this indication | |
| VSV-IFNβ-NIS | Phase 2 | Oncolytic virus | Oncolytic VSV expressing interferon-beta and NIS | not yet graded | No reviewed efficacy summary in this indication | |
| Adipose-Derived MSC Clusters (S.Biomedics) | Phase 1/2(overall) | Cell therapy | No discrete molecular target | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| BGC101 | Phase 1/2(overall) | Cell therapy | No discrete molecular target | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Evalstotug | Phase 1/2 | Biologic (subtype unspecified) | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| OBX-115 | Phase 1/2 | Cell therapy | IL-15 receptor signaling | not yet graded | No reviewed efficacy summary in this indication | |
| ALF202 | Phase 1(overall) | Cell therapy | No discrete molecular target | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| Naporafenib | Discontinued | Small molecule | Pan-RAF | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Vusolimogene oderparepvec (Tudriqev) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (2)
2029 (2)
July 2029 (1)
What to watch
October 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent